Amyvid® is a radioactive diagnostic agent developed by Avid Radiopharmaceuticals, a Penn start-up co-founded by Hank Kung, PhD, Emeritus Professor of Radiology at Penn Medicine, which was subsequently acquired by Eli Lilly. The updated label will support expanded use of Amyvid® in aiding the selection of patients who may benefit from amyloid-targeting therapies for Alzheimer’s disease and other causes of cognitive decline. Read more here.